Iris BioTechnologies is focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions. Iris has launched its proprietary BioWindows™ 2.0 to further the progress of personalized and targeted medicine.
In his inaugural speech President Obama stated, "We will restore science to its rightful place and wield technology's wonders to raise health care's quality and lower its cost." As a junior senator from Illinois Mr. Obama introduced S.B. 3822, "The Genomics and Personalized Medicine Act." The Act's goal is to "improve access to and appropriate utilization of valid, reliable, and accurate molecular genetic tests by all populations, thus helping to secure the promise of personalized medicine for all Americans."
The new administration's vision is clear but without the proper technologies the road is blocked. For the past ten years Simon Chin, Founder and CEO of Iris BioTechnologies, and his team have been developing the necessary tools to make the President's vision of personalized medicine for all Americans a reality. These include the Iris BioWindows™ informatics system and Nano-Biochip™ gene-profiling platform, a powerful combination that enables the practice of personalized medicine through the analysis of gene profiles and comprehensive life dynamics.
BioWindows™ is a HIPAA compliant, web based, medical information storage system that allows participants to grant selective or full sharing capabilities of their confidential medical and lifestyle information to physicians or family members anywhere in the world. This allows families to build multi-generational medical family trees that will help assure that they receive more personalized care now and in the future - the right medical treatment for the right patient at the right time. Many users of the system consider it their essential "Medical Passport" as they and their children and grandchildren participate in our increasingly global society.
The other essential tool for personalized medicine is the ability to measure the behavior of the many genes that are malfunctioning in any particular disease. The major diseases that inflict so much pain and suffering on our population are not caused by the inheritance of faulty genes but by genes malfunctioning over time due to lifestyle and other easily measured factors. The Iris Nano-Biochip™ platform is designed to clinically measure each patient's unique genomic profile.
Combining these two tools, BioWindows™ and the Nano-Biochip™, will offer physicians a unique perspective concerning the relationship of a patient's genes and their lifestyle dynamics, according to Mr. Chin. Armed with this information clinicians can truly personalize their medical treatments raising the quality of our health care system and lowering its cost.
Iris BioTechnologies has dedicated the past decade to developing the necessary tools and technologies to help eradicate breast cancer. Disease eradication will only come from a mobilized grass roots effort by millions of concerned citizens with access to the proper tools. Won't it be nice when we can answer our 44th President's "yes we can" challenge with "yes we did" eradicate breast cancer.